Skip to search formSkip to main contentSkip to account menu

BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I

Known as: BCR-ABL1 T315I Mutation, BCR-ABL Thr315Ile Mutation, BCR/ABL Fusion Protein with T315I 
A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.944C>T mutation. This protein is comprised of the N-terminus of the… 
National Institutes of Health

Related topics

Related topics

6 relations
BCR-ABL Fusion GeneFusion GeneNeoplastic Cell TransformationOncogenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Interferon regulatory factor 5 (IRF5) modulates the expression of genes controlling cell growth and apoptosis. Previous findings… 
2014
2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
In the face of competing tyrosine kinase inhibitors (TKIs), identification of chronic myeloid leukemia (CML) patients expecting… 
2014
2014
Targeting Catalase but Not Peroxiredoxins Enhances Arsenic Trioxide-Induced Apoptosis in K562 Cells
Despite considerable efficacy of arsenic trioxide (As2O3) in acute promyelocytic leukemia (APL) treatment, other non-APL… 
2012
2012
Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.
WhenIstartedmycareerinleukemiaresearch,interferonalfa was standard therapy for patients with chronic myeloid leukemia (CML… 
2010
2010
ABL Alternative Splicing Is Quite Frequent in Normal Population - Letter
In the article by Lee et al. (1), an alternative splicing of BCR-ABL is proposed as a mechanism for imatinib resistance in… 
2006
2006
MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with…
MK-0457 (VX-680) is a small molecule inhibitor of aurora kinases A, B, and C, FLT3, and JAK-2 with nanomolar level broad spectrum… 
Highly Cited
2005
Highly Cited
2005
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
Resistance to imatinib during the treatment of chronic myeloid leukaemia (CML) is frequently associated with point mutations in… 
2000
2000
Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML
Molecular analysis of the Philadelphia (Ph) chromosome has shown that the 39 sequences of the tyrosine kinase c-ABL proto… 
1998
1998
A polymorphism in exon b2 of the major breakpoint cluster region (M‐bcr) identified in chronic myeloid leukaemia patients
The BCR/ABL junctional region and the b3 exon from chronic myeloid leukaemia (CML) patients were sequenced. In all 21 samples… 
1988
1988
Rearrangement of the Breakpoint Cluster Region and Expression of P210 BCR-ABL in a "Masked" Philadelphia Chromosome-Positive Acute Myeloid Leukemia
The Philadelphia (Ph) translocation t(9;22)(q34;q11) occurs frequently in chronic myeloid leukemia (CML) but is less common in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)